Early initiation of PerIpheral VasOpressors for sepsis Treatment in sub- Saharan Africa (PIVOT-Africa) (360G-Wellcome-352259_Z_26_Z)
Sepsis is a leading cause of mortality globally, with an estimated 85% of the global sepsis deaths disproportionately occurring in low- and middle-income countries, particularly in sub-Saharan Africa where access to intensive care and advanced haemodynamic support is limited. To reduce mortality, early management is paramount. Although strategies emphasise intravenous fluid administration, trials in sub-Saharan Africa have demonstrated increased mortality associated with liberal fluid resuscitation. The haemodynamic management for adults with sepsis-induced hypoperfusion within sub-Saharan Africa remains unknown. We hypothesise that early peripherally-administered vasopressor therapy, combined with a conservative fluid strategy, will improve through restoration of perfusion, while reducing fluid-associated harm. To date, this strategy has not been evaluated in sub-Saharan Africa. We will develop a randomised controlled clinical trial (RCT) protocol to evaluate an early peripheral vasopressor intervention compared with usual care in adults with sepsis-induced hypoperfusion in Uganda and Malawi. Protocol development will be informed by structured engagement with policymakers, clinicians, and patients, alongside targeted pilot studies to refine the intervention and trial design. The output will be a definitive RCT protocol designed to inform context-appropriate sepsis guidelines and future policy in sub-Saharan Africa. Keywords: sepsis, vasopressors, fluid resuscitation, sub-Saharan Africa, clinical trial, global health, critical care
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2026-07-13T00:00:00+00:00 |
| Internal ID | 352259/Z/26/Z |
| Planned Dates: End Date | 2028-12-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2027-01-01T00:00:00+00:00 |
| Amount Awarded | 96082.11 |
| Financial Year | 2025/26 |
| Lead Applicant | Dr Jane Nakibuuka |
| Grant Programme: Title | Infectious Disease Clinical Trial Development Award |
| Partnership Name | Wellcome-FCDO Collaborative Strategic Partnership |
| Applicant Surname | Nakibuuka |
| Approval Committee | Infectious Disease Clinical Trial Development Award |
| Other Applicant(s) | Dr Stephen Andrew Spencer, Dr Rhona Mijumbi-Deve, Dr Felix Limbani, Dr Marc Yves Romain Henrion, Dr Shevin T Jacob, Prof Eve Worrall, Prof Paul Dark |
| Recipient Org: Country | Uganda |
| Recipient Org: City | Kampala |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | Yes |
| Total amount including partnership funding | 201515.2 |